Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

End-of-day quote. End-of-day quote  - 11/23
2.885 USD   -9.56%
11/21 IMMUNOCELLULAR : Reports Updated Immune Monitoring Data from ICT-10..
11/21 IMMUNOCELLULAR : REVERSE SPLIT: 1 of 40
11/21 IMMUNOCELLULAR : REVERSE SPLIT: 1 of 40
 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 0,75 M
EBIT 2016 -22,1 M
Net income 2016 -21,1 M
Debt 2016 -
Yield 2016 -
Sales 2017 2,15 M
EBIT 2017 -23,3 M
Net income 2017 -24,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 12,2x
Capi. / Sales2017 4,26x
Capitalization 9,16 M
More Financials
Company
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers.ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent... 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
12/01 IMMUNOCELLULAR THERAPEUTICS : Reports Updated Immune Monitoring Data from ICT-10..
11/21 IMMUNOCELLULAR THERAPEUTICS : Reports Updated Immune Monitoring Data from ICT-10..
11/21 IMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40
11/21 IMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40
11/18 IMMUNOCELLULAR THERAPEUTICS, LTD. : Amendments to Articles of Inc. or Bylaws; Ch..
11/10 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
11/10 IMMUNOCELLULAR THERAPEUTICS : Announces Third Quarter 2016 Financial Results and..
11/04 IMMUNOCELLULAR THERAPEUTICS, LTD. : Other Events, Financial Statements and Exhib..
11/02 IMMUNOCELLULAR THERAPEUTICS : to Report Third Quarter 2016 Financial Results on ..
09/16 IMMUNOCELLULAR THERAPEUTICS, LTD. : Change in Directors or Principal Officers (f..
More news
Sector news : Biotechnology & Medical Research - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/10 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
11/10 ImmunoCellular Therapeutics EPS in-line
08/22 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
08/22 ImmunoCellular Therapeutics beats by $0.01
06/07 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,00 $
Spread / Average Target 88%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Gengos President, Chief Executive Officer & Director
Gary S. Titus Chairman
David E. Fractor Principal Financial & Accounting Officer
Steven J. Swanson Senior Vice President-Research
John S. Yu Secretary & Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..797.83%9
INCYTE CORPORATION-5.68%18 825
QUINTILES IMS HOLDINGS..11.90%17 971
CELLTRION, INC.--.--%10 097
SEATTLE GENETICS, INC.44.41%9 443
LONZA GROUP AG11.34%9 288
More Results